Ambrilia Reports Positive Results From Phase II Octreotide Study

Ambrilia Biopharma reported positive topline results from the first clinical study of its prolonged release formulation of Octreotide in acromegalic patients.

Ambrilia said that data from a single-dose administration of Octreotide (C2L) in eight patients indicated that the drug normalizes the major marker for acromegaly and suppresses high growth hormone plasma levels.

Efficacy and pharmacokinetic data suggested a 42-day dosing interval for Octreotide, compared with a 28-day dosing interval for the original product, Sandostatin LAR, the company added.

Ambrilia’s prolonged release formulation of Octreotide is currently in clinical Phase III studies. The company added that it has completed patient recruitment for the pivotal efficacy study, which it expects to complete by the end of the year.